These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22974232)

  • 21. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 22. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
    Krayem M; Najem A; Journe F; Morandini R; Sales F; Awada A; Ghanem GE
    Oncotarget; 2024 Jun; 15():354. PubMed ID: 38829662
    [No Abstract]   [Full Text] [Related]  

  • 24. Is it good or bad to find a BRAF mutation?
    Flaherty KT
    J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.
    Lezcano C; Lee CW; Larson AR; Menzies AM; Kefford RF; Thompson JF; Mihm MC; Ogino S; Long GV; Scolyer RA; Murphy GF
    Mod Pathol; 2014 Sep; 27(9):1193-202. PubMed ID: 24434899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptive resistance to RAF inhibitors in melanoma.
    Kugel CH; Aplin AE
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1032-8. PubMed ID: 24828387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
    Rajakulendran T; Adam DN
    Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance.
    Alcalá AM; Flaherty KT
    Clin Cancer Res; 2012 Jan; 18(1):33-9. PubMed ID: 22215904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for malignant melanoma.
    Lorentzen HF
    Curr Opin Pharmacol; 2019 Jun; 46():116-121. PubMed ID: 31261023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
    Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
    Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
    Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
    J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
    [No Abstract]   [Full Text] [Related]  

  • 33. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy-induced tumour secretomes promote resistance and tumour progression.
    Obenauf AC; Zou Y; Ji AL; Vanharanta S; Shu W; Shi H; Kong X; Bosenberg MC; Wiesner T; Rosen N; Lo RS; Massagué J
    Nature; 2015 Apr; 520(7547):368-72. PubMed ID: 25807485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.
    Kwong LN; Boland GM; Frederick DT; Helms TL; Akid AT; Miller JP; Jiang S; Cooper ZA; Song X; Seth S; Kamara J; Protopopov A; Mills GB; Flaherty KT; Wargo JA; Chin L
    J Clin Invest; 2015 Apr; 125(4):1459-70. PubMed ID: 25705882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new BRAF inhibitor breaks resistance barriers.
    Scotece M; Drosten M
    Trends Cancer; 2024 Jul; 10(7):576-578. PubMed ID: 38866669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the PI3K-AKT pathway in melanoma.
    Davies MA
    Cancer J; 2012; 18(2):142-7. PubMed ID: 22453015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.